Table 2.

Enrichment of Immune Suppression in the Mesenchymal Glioblastoma Subset

Immune suppressor/gene		PMID reference	Number of cases; % mRNA over expression
			Proneural n=141	Mesenchymal n=160	Classical n=147	Neural n=96
Immune suppressive cytokines and checkpoints	Galectin-3/LGALS3	22672152	2; 1	28; 18	13; 9	6; 6
	VEGF/VEGFA	20549821	16; 11	26; 16	32; 22	3; 3
	IL-10/IL10	22981868	4; 3	39; 24	5; 3	13; 14
	IL-23/IL23A	20404142	4; 3	21; 13	12; 8	5; 5
	TGF-β/TGFB1	9597127	5; 4	50; 31	14; 10	2; 2
	PD-1/SPATA2	11209085	28; 20	14; 9	58; 39	27; 28
	PD-L1/PDL1	22180678	0; 0	25; 16	14; 10	5; 5
	CTLA-4/CTLA-4	20578982	12; 9	30; 19	8; 5	11; 11
Tumor-supportive macrophage chemotactic and skewing molecules	CSF-1/CSF	14709771	3; 2	30; 19	4, 3	1, 1
	CCL2/CCL2	22162712	5; 4	53; 33	9; 6	7; 7
	CCL-22/CCL22	20518016	10; 7	33; 21	17; 12	12; 13
	CD163/CD163	15478309	8; 6	60; 38	2; 1	11; 11
	CD204/MSR1	22083206	5; 4	53; 33	3; 2	8; 8
	MIC-1/GDF15	20534737	7; 5	43; 27	25; 17	14; 15
	Arginase/ARG1	20643302	9; 6	23; 14	16; 11	22; 23
	CD47/CD47	19666525	15; 11	30; 19	10; 7	19; 20
Immune suppressive signaling pathways	IL-6/IL6	23248265	32; 23	83; 52	16; 11	15; 16
	gp130/IL6ST	20610800	0; 0	25; 16	17; 12	8; 8
	Jak2	22684105	6; 4	22; 14	9; 6	11; 11
	STAT3/STAT3	20053772	8; 6	31; 19	26; 18	0; 0
	Pim-1/PIM1	22384197	4; 3	44; 28	13; 9	6; 6
	SOCS3/SOCS3	10837055	5; 4	36; 23	10; 7	3; 3
	STAT5A/STAT5A	12835478	4; 3	48; 30	10; 7	2; 2
Markers of Tregs	CD4/CD4	20605226	5; 4	57; 36	0; 0	9; 9
	CD278/ICOS	23026134	8; 6	23; 14	9; 6	9; 9
	IDO/IDO1	22932670	6; 4	25; 16	14; 10	4; 4
	FoxP3/FOXP3	20068105	0; 0	0; 0	0; 0	0; 0

Red denotes preferential statistically significant enrichment (p<0.05) of mRNA expression in the comparison of the mesenchymal versus proneural subset.